Merck announced that the European Commission has approved KEYTRUDA, Merck’s anti-PD-1 therapy, as a monotherapy for the adjuvant treatment of adults with non-small cell lung cancer who are at high risk of recurrence following complete resection and platinum-based chemotherapy. The decision marks fifth approval for KEYTRUDA in lung cancer in the EU.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MRK:
- Merck (NYSE:MRK) Urges UK Government to Support Pharma
- Merck adopts opinion recommending approval of Keytruda
- Merck: KEYNOTE-671 trial meets dual primary endpoint of OS
- Merck announces AMBASSADOR trial meets one of two primary endpoints of DFS
- Merck’s new application for sotatercept given priority review by FDA